MCID: MYL001
MIFTS: 51

Myelitis

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Myelitis

MalaCards integrated aliases for Myelitis:

Name: Myelitis 12 74 52 54 6 43 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:322
MeSH 43 D009187
NCIt 49 C26832
SNOMED-CT 67 41370002
UMLS 71 C0026975

Summaries for Myelitis

Disease Ontology : 12 A spinal cord disease that is characterized by inflammation of the white matter or gray matter of the spinal cord.

MalaCards based summary : Myelitis is related to external pathological resorption and scorpion envenomation. An important gene associated with Myelitis is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mitoxantrone and Analgesics have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 74 Myelitis is inflammation of the spinal cord which can disrupt the normal responses from the brain to the... more...

Related Diseases for Myelitis

Diseases related to Myelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 575)
# Related Disease Score Top Affiliating Genes
1 external pathological resorption 10.6 TNF IL6
2 scorpion envenomation 10.6 TNF IL6
3 neuromyelitis optica spectrum disorder 10.6 CD27 AQP4
4 punctate inner choroidopathy 10.6 TNF IL10
5 tropical endomyocardial fibrosis 10.6 TNF IL10
6 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 TNF IL6
7 multifocal choroiditis 10.5 TNF IL10
8 autoimmune inner ear disease 10.5 TNF MMP9
9 spotted fever rickettsiosis 10.5 TNF IL10
10 neonatal stroke 10.5 MTHFR AQP4
11 eales disease 10.5 TNF IL6 IL10
12 angelucci's syndrome 10.5 IL17A CXCL8
13 idiopathic anterior uveitis 10.5 TNF IL6 CXCL8
14 streptococcal toxic-shock syndrome 10.5 TNF IL6 CXCL8
15 dermatitis, atopic, 8 10.5 IL10 CXCL8
16 hand, foot and mouth disease 10.5 IL6 IL10 AQP4
17 palladium allergic contact dermatitis 10.5 TNF IL17A IL10
18 papillary conjunctivitis 10.5 IL6 CXCL8 CCL11
19 giant papillary conjunctivitis 10.5 IL6 CXCL8 CCL11
20 beryllium disease 10.4 TNF HLA-DPB1
21 acute generalized exanthematous pustulosis 10.4 IL17A CXCL8
22 chemical colitis 10.4 TNF IL17A IL10
23 irritant dermatitis 10.4 TNF IL6 CXCL8
24 vascular myelopathy 10.4 MOG AQP4
25 bagassosis 10.4 TNF IL6 CXCL8
26 thyroiditis 10.4 TNF IL6 IL10
27 systemic autoimmune disease 10.4 MMP9 IL6 IL17A
28 blood group, globoside system 10.4 TNF IL6 CXCL8
29 fuchs' heterochromic uveitis 10.4 IL6 CXCL8
30 macular retinal edema 10.4 TNF IL6 CXCL8
31 meconium aspiration syndrome 10.4 TNF IL6 CXCL8
32 vitreous disease 10.4 TNF IL6 CXCL8
33 spinal cord infarction 10.4 MTHFR APOH
34 endophthalmitis 10.4 TNF IL6 CXCL8
35 scabies 10.4 IL10 CXCL8 CCL11
36 neurosyphilis 10.4 IL17A IL10 CXCL8
37 retinitis pigmentosa 55 10.4 TNFRSF1A TNF IL6
38 erythema multiforme 10.4 TNF IL6 CXCL8
39 milk allergy 10.4 TNF IL9 IL10
40 null-cell leukemia 10.4 TNF IL6
41 haemophilus influenzae 10.4 TNF CXCL8
42 lambert-eaton myasthenic syndrome 10.4 TNF IL10 AMPH
43 decubitus ulcer 10.4 TNF MMP9 IL6
44 endometritis 10.4 TNF IL6 CXCL8
45 chronic beryllium disease 10.4 TNF HLA-DPB1
46 apnea, obstructive sleep 10.4 TNF IL6 CXCL8
47 neonatal jaundice 10.4 TNF IL6 IL10
48 clonorchiasis 10.4 TNF IL10 CXCL8
49 toxicodendron dermatitis 10.4 TNF CXCL8
50 rheumatic heart disease 10.4 TNF IL6 IL10

Graphical network of the top 20 diseases related to Myelitis:



Diseases related to Myelitis

Symptoms & Phenotypes for Myelitis

GenomeRNAi Phenotypes related to Myelitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 APOH CD40LG CXCL8 IL10 IL17A TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 APOH CD40LG CXCL8 IL10 IL17A TNF

MGI Mouse Phenotypes related to Myelitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.21 AQP4 CCL11 CCR6 CD27 CD40LG IL10
2 homeostasis/metabolism MP:0005376 10.13 APOH AQP4 CCR6 CD40LG IL10 IL17A
3 immune system MP:0005387 10.1 AQP4 CCL11 CCR6 CD27 CD40LG IL10
4 digestive/alimentary MP:0005381 10.01 AQP4 IL10 IL17A IL6 IL9 MMP9
5 nervous system MP:0003631 9.93 AMPH AQP4 CCR6 CD40LG IL10 IL6
6 respiratory system MP:0005388 9.56 AQP4 CCL11 IL10 IL17A IL6 MMP9
7 vision/eye MP:0005391 9.28 AQP4 IL10 IL6 MBP MMP9 MOG

Drugs & Therapeutics for Myelitis

Drugs for Myelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
2 Analgesics Phase 4
3 Topoisomerase Inhibitors Phase 4
4
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
5
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
6
Ravulizumab Approved, Investigational Phase 3 1803171-55-2
7 Antineoplastic Agents, Immunological Phase 2, Phase 3
8 Complement System Proteins Phase 3
9 Complement Inactivating Agents Phase 3
10 Immunoglobulins Phase 3
11 Antibodies Phase 3
12 Rho(D) Immune Globulin Phase 3
13 gamma-Globulins Phase 3
14 Immunoglobulins, Intravenous Phase 3
15 Vaccines Phase 3
16
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
17
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
18
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
19
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
20
4-Aminopyridine Approved Phase 1, Phase 2 504-24-5 1727
21
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
22 Immunoglobulin G Phase 2
23 Pharmaceutical Solutions Phase 1, Phase 2
24 Antibodies, Monoclonal Phase 1, Phase 2
25 Thymoglobulin Phase 1, Phase 2
26 Alkylating Agents Phase 1, Phase 2
27
Isophosphamide mustard Phase 1, Phase 2 0
28 Antilymphocyte Serum Phase 1, Phase 2
29 polysaccharide-K Phase 1, Phase 2
30 Potassium Channel Blockers Phase 1, Phase 2
31 Fibrinolytic Agents Phase 2
32 Plasminogen Phase 2
33 Tissue Plasminogen Activator Phase 2
34
Bevacizumab Approved, Investigational Phase 1 216974-75-3
35 Angiogenesis Inhibitors Phase 1
36 Complement C1s Phase 1
37 Complement C1 Inhibitor Protein Phase 1
38 Complement C1 Inactivator Proteins Phase 1
39
Ergocalciferol Approved, Nutraceutical 50-14-6 5280793
40
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
41
Calcium Approved, Nutraceutical 7440-70-2 271
42 Autoantibodies
43 Micronutrients
44 Vitamins
45 Trace Elements
46 Nutrients
47 Ergocalciferols
48 Vitamin D2
49 Calciferol
50 Calcium, Dietary

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
2 Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS10) Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
3 An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results. Withdrawn NCT00037115 Phase 4 interferon beta 1a;methotrexate;methylprednisolone
4 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
5 Randomized Clinical Trial of Plasma Exchanges Versus Sham Plasma Exchanges in Disabling Multiple Sclerosis Acute Relapses Refractory to Steroid Treatment Completed NCT01442233 Phase 3
6 A Randomized, Double-Blind, Multicenter, Parallel-Group Comparative Phase III Study Evaluating the Efficacy and Safety of TAK-816 Compared With ActHIB in Healthy Infants Completed NCT01379846 Phase 3
7 Comparison of Annual Relapse Rate, Expanded Disability Status Scale, and Side Effects Between Azathioprine and Rituximab in Patients With Neuromyelitis Optica Spectrum Disorders Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
8 A Phase III Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants and Children Completed NCT01569581 Phase 3
9 A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) Recruiting NCT04201262 Phase 3
10 A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) Active, not recruiting NCT02003144 Phase 3
11 A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum Disorder Not yet recruiting NCT04155424 Phase 2, Phase 3 Eculizumab
12 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin (IVIg) Versus Standard Therapy for the Treatment of Transverse Myelitis in Adults and Children Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
13 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) Terminated NCT01892345 Phase 3 Eculizumab;Placebo
14 Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
15 Efficacy of Dose Intensified Radiotherapy of Spinal Metastases of Solid Tumors by Dose Increased, Homogeneous Radiation of Vertebral Body and Simultaneous Application of Stereotactic Boost. Unknown status NCT01849510 Phase 2
16 Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study Unknown status NCT02591901 Phase 2 Uro vaxom
17 Double-Blind, Placebo-Controlled Crossover Trial on the Safety and Efficacy of Sustained-Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
18 A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (Omr-IgG-am) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus(WNV) Completed NCT00069316 Phase 2 Omr-IgG-am
19 A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (OMR-IGG-AM) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus (WNV) Encephalitis and/or Myelitis Completed NCT00068055 Phase 1, Phase 2 Omr-lgG-am;Polygam® S/D;Placebo
20 Single-center, Open Label Trial of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active Neuromyelitis Optica Spectrum Disorders (NMOSD) Completed NCT03062579 Phase 1, Phase 2 Tocilizumab
21 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
22 A Phase II Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants Completed NCT01512706 Phase 2
23 Trial of High Dose Immunosuppressive Therapy With Hematopoietic Stem Cell Support in Devic's Disease Active, not recruiting NCT00787722 Phase 1, Phase 2 Cyclophosphamide;G-CSF;rATG;Mesna;Rituximab;Methylprednisolone
24 A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Transverse Myelitis (TM) Not yet recruiting NCT03887273 Phase 1, Phase 2
25 A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma Not yet recruiting NCT04026568 Phase 1, Phase 2 4-Aminopyridine;Placebo oral tablet
26 Thrombolysis in Ischemic Spinal Cord Stroke Terminated NCT02242084 Phase 2 Intravenuse Alteplase
27 A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of ABX-1431 in Patients With Central Pain Completed NCT03138421 Phase 1 ABX-1431 HCl;Placebo
28 An Open-label Phase 1b Study of Avastin® (Bevacizumab) for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD). Completed NCT01777412 Phase 1 Bevacizumab
29 Phase I, Single-Center, Open Label Trial of Ublituximab + Glucocorticoids for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) Completed NCT02276963 Phase 1 Ublituximab
30 Phase 1b Study of C1-esterase Inhibitor (Cinryze) With Standard of Care for Acute Treatment of Neuromyelitis Optica Exacerbations Completed NCT01759602 Phase 1 C1-esterase inhibitor (Cinryze)
31 Open Label Study of Safety and Tolerability of Rituximab in Neuromyelitis Optica, Recurrent Transverse Myelitis and Recurrent Bilateral Simultaneous Optic Neuritis Completed NCT00501748 Phase 1 Rituximab
32 A Phase I Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Adults, Children and Infants Completed NCT01391494 Phase 1
33 An Exploratory Study of the Safety, Tolerability, Pharmacokinetics and Potential Effectiveness of AVI-4020 Injection in Patients Presenting With Presumptive Acute Neuroinvasive West Nile Virus (WNV) Disease Terminated NCT00091845 Phase 1 AVI-4020 Injection
34 Proposal for a Non-randomized, Patient Sponsored, Multi-center Study Studying the Impact and Safety of the Utilization of Culture Expanded Autologous, Adipose-derived Mesenchymal Stem Cells Deployed Via Intravenous Injection for the Treatment of Multiple Sclerosis Terminated NCT02326935 Phase 1
35 A Single Center Open Label Pilot Study of Alpha1-Antitrypsin: A Novel Treatment to Mitigate Neuromyelitis Optica Attacks Withdrawn NCT02087813 Phase 1 Alpha1-antitrypsin;methylprednisolone
36 Evaluation of Macular and Retinal Nerve Fiber Layer Thickness Measurements for Detection of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Optical Coherence Tomography. Unknown status NCT01024985
37 The French Multiple Sclerosis Registry Unknown status NCT02889965
38 Management of Acute Disseminated Encephalomyelitis in Neurology Unit of Assiut University Children Hospital Unknown status NCT03284801
39 A Phase IV Study to Assess the Safety of Menveo Vaccine Being Used by HMO Subjects Aged 11-21 Years of Age Completed NCT01452464
40 Investigation of the Natural History of West Nile Virus Infection in Patients With Recently Acquired West Nile Fever or Neuroinvasive Disease Completed NCT00069303
41 Evaluating the Effectiveness of a Serious Game to Enhance Self-Management Skills Among Adolescents and Young Adults With Spinal Cord Dysfunction Completed NCT02341950
42 Injured Spinal Cord Pressure Evaluation Study - Transverse Myelitis Recruiting NCT03336762
43 Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate or CAPTURE Study Recruiting NCT02144935
44 Collaboration on Neuroimmunology: Question, Understand, Educate, Restore - The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders Recruiting NCT01623076
45 PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes. Recruiting NCT03942952
46 The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS) Recruiting NCT02850705
47 A Clinical Observational Follow-up Study of European Pediatric Cases of Acute Flaccid Myelitis Associated With EV-D68 Infection. Recruiting NCT03499366
48 Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia Recruiting NCT03206541
49 Large-scale, Multi-disciplinary Sample and Data Repository for Multiple Sclerosis and Related Demyelinating Diseases Active, not recruiting NCT00445367
50 A Prospective Observational Study of Maintenance Plasma Exchange (PLEX) for Neuromyelitis Optica Spectrum Disorders (MultiPLEX Study) Active, not recruiting NCT01500681

Search NIH Clinical Center for Myelitis

Cochrane evidence based reviews: myelitis

Genetic Tests for Myelitis

Anatomical Context for Myelitis

MalaCards organs/tissues related to Myelitis:

40
Spinal Cord, Brain, Bone, Lung, B Cells, T Cells, Bone Marrow

Publications for Myelitis

Articles related to Myelitis:

(show top 50) (show all 4399)
# Title Authors PMID Year
1
Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. 54 61
19917985 2009
2
[A case of anti-AQP4 antibody-positive recurrent myelitis overlapped with autoimmune disorders including incomplete CREST syndrome revealed multiple discontinuous cord lesions]. 54 61
19348177 2009
3
Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. 54 61
19140826 2009
4
A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. 54 61
18509235 2008
5
Ascending myelitis in association with herpes simplex virus. A case report. 54 61
9436377 1997
6
Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis optica spectrum disorders. 61
31986374 2020
7
Anti-myelin oligodendrocyte glycoprotein antibody associated disease spectrum - A north Indian tertiary care centre experience and review of literature. 61
31931436 2020
8
Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related adverse reactions in the nervous system. 61
31823509 2020
9
Nontraumatic Myelopathy in Malawi: A Prospective Study in an Area with High HIV Prevalence. 61
31837130 2020
10
Clinical characteristics of enterovirus A71 neurological disease during an outbreak in children in Colorado, USA, in 2018: an observational cohort study. 61
31859216 2020
11
MOG-IgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity. 61
31641876 2020
12
The Emergent Evaluation and Treatment of Neck and Back Pain. 61
31757249 2020
13
Transverse Myelitis in Systemic Lupus Erythematosus: Clinical Features and Prognostic Factors in a Large Cohort of Latin American Patients. 61
32028309 2020
14
Cognitive functions in Egyptian neuromyelitis optica spectrum disorder. 61
31790906 2020
15
CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease. 61
31582425 2020
16
Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients. 61
31532865 2020
17
MIF -173G/C polymorphism is associated with NMO disease severity. 61
31790982 2020
18
Overlapping autoimmune syndrome: A case of concomitant anti-NMDAR encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease. 61
31837635 2020
19
Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. 61
31743235 2020
20
Recurrent myelitis and asymptomatic hypophysitis in IgG4-related disease: case-based review. 61
31898763 2020
21
Neurosyphilis presenting with myelitis-case series and literature review. 61
31859039 2020
22
Characteristics of Patients with Acute Flaccid Myelitis, United States, 2015-2018. 61
31961305 2020
23
Acute flaccid myelitis temporally associated with rhinovirus infection: just a coincidence? 61
31654361 2020
24
Short segment myelitis as the initial and only manifestation of aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorders. 61
32010226 2020
25
Unmet Needs in the Evaluation, Treatment, and Recovery for 167 Children Affected by Acute Flaccid Myelitis Reported by Parents Through Social Media. 61
31630913 2020
26
Two Cases of Very-Late-Onset Neuromyelitis Optica Spectrum Disorder (NMOSD) in Patients over the Age of 80. 61
32009931 2020
27
Comparison of 2 collection methods for cerebrospinal fluid analysis from standing, sedate adult horses. 61
31977116 2020
28
Extrahepatic manifestations of hepatitis E virus: An overview. 61
31601068 2020
29
Acute Neuromuscular Disorders in the Pediatric Intensive Care Unit. 61
31502491 2020
30
Experience of Using Adrenocorticotropic Hormone in the Treatment of Patients With Acute Neuromyelitis Optica Who Failed Systemic Steroids: A Case Series. 61
31876792 2020
31
Disseminated Cryptococcosis revealed by transverse myelitis in Immunocompetent patient: a case report and review of the literature. 61
31924167 2020
32
Toxocariasis of the Nervous System. 61
31960218 2020
33
[Anti-myelin oligodendrocyte glycoprotein antibody associated encephalitis]. 61
31956198 2020
34
Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. 61
31757816 2020
35
Neurobrucellosis presenting as longitudinally extensive transverse myelitis: A case report and review of the literature. 61
32000119 2020
36
Neuromyelitis Optica Spectrum Disorder Causing Longitudinally Extending Transverse Myelitis -A Case Report. 61
31979654 2020
37
Deciphering anti-MOG IgG antibodies: Clinical and radiological spectrum, and comparison of antibody detection assays. 61
31954354 2020
38
Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population. 61
31932912 2020
39
Lack of evidence for Toxocara infection in Italian myelitis patients. 61
31332580 2020
40
Longitudinal Extensive Transverse Myelitis Secondary to Tuberculosis- A Case Report. 61
31979646 2020
41
A man in his fifties with variable weakness and difficulty in walking. 61
31823568 2019
42
Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. 61
31918241 2019
43
Contralateral Obturator Nerve to Femoral Nerve Transfer for Restoration of Knee Extension After Acute Flaccid Myelitis: A Case Report. 61
31850914 2019
44
Relief of Neuropathic Pain After Spinal Cord Stimulator Implantation in a Patient With Idiopathic Thoracic Transverse Myelitis: A Case Report. 61
31449073 2019
45
Acute Flaccid Myelitis: Characteristics and Outcomes of 2014 and 2016 Cases at a Single Center. 61
31402137 2019
46
Devic's index case: A critical reappraisal - AQP4-IgG-mediated neuromyelitis optica spectrum disorder, or rather MOG encephalomyelitis? 61
31726278 2019
47
Correction to: Abstracts from the 5th International Porto Congress of Multiple Sclerosis. 61
31686386 2019
48
Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. 61
31679449 2019
49
Neuromyelitis optica spectrum disorder and systemic lupus erythematosus. 61
31722604 2019
50
Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity. 61
30475082 2019

Variations for Myelitis

ClinVar genetic disease variations for Myelitis:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CACNA1A NM_001127221.1(CACNA1A):c.6128C>T (p.Thr2043Met)SNV Uncertain significance 386521 rs563345694 19:13323262-13323262 19:13212448-13212448
2 COL6A2 NM_001849.3(COL6A2):c.2008A>G (p.Thr670Ala)SNV Uncertain significance 598977 rs753298014 21:47545737-47545737 21:46125823-46125823

Expression for Myelitis

Search GEO for disease gene expression data for Myelitis.

Pathways for Myelitis

Pathways related to Myelitis according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 TNFRSF1A TNF MMP9 IL9 IL6 IL17A
2
Show member pathways
13.83 TNFRSF1A TNF IL9 IL6 IL17A IL10
3
Show member pathways
13.66 TNFRSF1A TNF IL9 IL6 IL17A IL10
4
Show member pathways
13.56 TNFRSF1A TNF IL9 IL6 IL17A IL10
5
Show member pathways
13.4 TNFRSF1A TNF IL9 IL6 IL17A IL10
6
Show member pathways
13.17 TNFRSF1A TNF IL9 IL6 IL17A IL10
7
Show member pathways
13.14 TNFRSF1A TNF MMP9 IL6 IL10 CXCL8
8
Show member pathways
13.14 TNFRSF1A TNF MMP9 IL9 IL6 IL17A
9
Show member pathways
12.83 TNFRSF1A TNF IL6 HLA-DPB1 CXCL8
10
Show member pathways
12.72 TNFRSF1A TNF IL9 IL6 CD40LG
11
Show member pathways
12.72 TNF IL9 IL6 IL17A IL10 HLA-DPB1
12
Show member pathways
12.66 TNFRSF1A TNF IL10 HLA-DPB1 CD40LG
13
Show member pathways
12.62 TNF IL9 IL6 IL17A IL10 CD40LG
14
Show member pathways
12.61 TNF IL6 IL17A IL10 HLA-DPB1
15 12.59 TNFRSF1A TNF IL17A IL10 CD40LG
16
Show member pathways
12.38 TNF MMP9 IL6 IL17A CXCL8 CCL11
17 12.36 TNFRSF1A TNF IL6 HLA-DPB1
18 12.32 TNFRSF1A TNF IL6 CXCL8
19
Show member pathways
12.29 TNFRSF1A TNF IL10 HLA-DPB1 CD40LG
20
Show member pathways
12.28 TNF IL9 IL6 IL17A IL10 CXCL8
21
Show member pathways
12.28 TNFRSF1A TNF IL6 IL10 CXCL8 CCR6
22 12.26 TNFRSF1A TNF IL6 IL10 HLA-DPB1
23 12.21 TNFRSF1A TNF MMP9 IL6
24
Show member pathways
12.21 TNF IL6 CXCL8 CCL11
25 12.18 TNF IL6 IL10 CXCL8 AQP4
26
Show member pathways
12.08 TNF IL6 IL17A IL10
27 12.04 TNF IL6 IL10 CXCL8
28 12 TNFRSF1A TNF MMP9 IL6
29 11.99 TNF MMP9 MBP IL6 CXCL8 AQP4
30 11.95 TNFRSF1A TNF CXCL8 CD40LG
31 11.95 TNF IL6 IL10 CXCL8
32 11.91 TNF IL6 IL17A HLA-DPB1 CXCL8
33 11.83 TNF IL9 IL17A IL10 CCR6
34 11.8 TNF IL6 IL10 CXCL8
35
Show member pathways
11.78 TNF CXCL8 CD40LG
36 11.76 TNF IL6 IL10
37
Show member pathways
11.76 TNFRSF1A TNF CD40LG
38 11.7 MMP9 IL6 CXCL8
39 11.69 TNF MMP9 IL6 CXCL8 CCL11
40 11.68 IL10 CD40LG CCL11
41 11.63 TNF IL6 CXCL8
42 11.6 IL10 CD40LG CD27
43 11.58 TNFRSF1A TNF IL6
44 11.57 TNF IL6 IL10 CXCL8 CD40LG
45 11.54 TNF MMP9 IL6
46 11.54 TNFRSF1A TNF IL6 IL10 CXCL8
47 11.53 IL6 CXCL8 CCL11
48 11.52 IL9 IL10 CCL11
49 11.48 TNF MMP9 IL6 IL17A IL10 CCL11
50 11.42 TNF IL6 IL10

GO Terms for Myelitis

Cellular components related to Myelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10 TNFRSF1A TNF MMP9 IL9 IL6 IL17A
2 cell surface GO:0009986 9.76 TNFRSF1A TNF MBP HLA-DPB1 CD40LG CD27
3 external side of plasma membrane GO:0009897 9.5 TNF MOG IL17A CD40LG CD27 CCR6
4 extracellular region GO:0005576 9.44 TNFRSF1A TNF MMP9 IL9 IL6 IL17A

Biological processes related to Myelitis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.81 TNF IL6 IL10 CXCL8
2 chemokine-mediated signaling pathway GO:0070098 9.77 CXCL8 CCR6 CCL11
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 TNFRSF1A TNF IL6
4 cytokine-mediated signaling pathway GO:0019221 9.76 TNFRSF1A TNF MMP9 IL6 IL17A IL10
5 response to glucocorticoid GO:0051384 9.75 TNF IL6 IL10
6 positive regulation of T cell proliferation GO:0042102 9.72 IL6 HLA-DPB1 CD40LG
7 humoral immune response GO:0006959 9.7 TNF IL6 CCR6
8 tumor necrosis factor-mediated signaling pathway GO:0033209 9.67 TNFRSF1A TNF CD40LG CD27
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.65 TNF MMP9 IL10
10 positive regulation of ceramide biosynthetic process GO:2000304 9.62 TNFRSF1A TNF
11 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.61 MBP IL10
12 regulation of neuroinflammatory response GO:0150077 9.61 MMP9 IL6
13 positive regulation of interleukin-6 secretion GO:2000778 9.61 TNF MBP IL17A
14 inflammatory response GO:0006954 9.61 TNFRSF1A TNF IL9 IL6 IL17A IL10
15 negative regulation of lipid storage GO:0010888 9.58 TNF IL6
16 endothelial cell apoptotic process GO:0072577 9.57 TNF IL10
17 death-inducing signaling complex assembly GO:0071550 9.56 TNFRSF1A TNF
18 regulation of establishment of endothelial barrier GO:1903140 9.54 TNFRSF1A TNF
19 positive regulation of JAK-STAT cascade GO:0046427 9.5 TNF IL6 IL10
20 negative regulation of cytokine secretion involved in immune response GO:0002740 9.49 TNF IL10
21 regulation of immunoglobulin secretion GO:0051023 9.46 TNF CD40LG
22 negative regulation of neurogenesis GO:0050768 9.43 TNF IL6 CCL11
23 receptor biosynthetic process GO:0032800 9.4 TNF IL10
24 immune response GO:0006955 9.36 TNF MBP IL9 IL6 IL17A IL10

Molecular functions related to Myelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 TNF IL9 IL6 IL17A IL10 CXCL8

Sources for Myelitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....